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POSACONAZOLE TREATMENT OF REFRACTORY EUMYCETOMA AND CHROMOBLASTOMYCOSIS
Ricardo NEGRONI(1), Angela TOBÓN(2), Beatriz BUSTAMANTE(3), Maria Aparecida SHIKANAI-YASUDA(4), Hernando PATINO(5) & Angela RESTREPO(2)
SUMMARY
Eumycetoma and chromoblastomycosis are chronic, disfiguring fungal infections of the subcutaneous tissue that rarely resolve
spontaneously. Most patients do not achieve sustained long-term benefits from available treatments; therefore, new therapeutic
options are needed. We evaluated the efficacy of posaconazole, a new extended-spectrum triazole antifungal agent, in 12 patients
with eumycetoma or chromoblastomycosis refractory to existing antifungal therapies.
Posaconazole 800 mg/d was given in divided doses for a maximum of 34 months. Complete or partial clinical response was
considered a success; stable disease or failure was considered a nonsuccess.
All 12 patients had proven infections refractory to standard therapy. Clinical success was reported for five of six patients with
eumycetoma and five of six patients with chromoblastomycosis. Two patients were reported to have stable disease. As part of a
treatment-use extension protocol, two patients with eumycetoma who initially had successful outcome were successfully retreated
with posaconazole after a treatment hiatus of > 10 months. Posaconazole was well tolerated during long-term administration (up
to 1015 d).
Posaconazole therapy resulted in successful outcome in most patients with eumycetoma or chromoblastomycosis refractory to
standard therapies, suggesting that posaconazole may be an important treatment option for these diseases.
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INTRODUCTION
Eumycetoma and chromoblastomycosis are chronic fungal
infections involving cutaneous and subcutaneous tissues caused by
direct inoculation through the skin1,2,5,10,17,23,32,35,36,53,57. In the case of
eumycetoma, other tissues are also attacked, including bones and
joints19,27. Although both mycoses present a widespread geographical
distribution, they are most common in tropical countries7,9,35,36.
Posaconazole is a new, extended-spectrum triazole antifungal agent
that has demonstrated in vitro activity against many of the fungal
pathogens that cause eumycetoma and chromoblastomycosis, including
S. apiospermum14,33,43,49, P. boydii16,20,43,52, and Fonsecaea spp.
Additionally, it has demonstrated clinical activity against filamentous
and other fungi, including those resistant to amphotericin B and/or
itraconazole, suggesting it may provide broad clinical usefulness in
the treatment of fungal infections24,34,51. Furthermore, posaconazole has
demonstrated in vivo activity against P. boydii20 and S. apiospermum34.
We report on the efficacy and safety of posaconazole in the
treatment of 12 patients with eumycetoma or chromoblastomycosis.
These patients were part of a large, multinational, open-label study
conducted to assess the safety and efficacy of posaconazole in patients
(N = 330) with invasive fungal infections who were intolerant of, or
who had disease refractory to conventional antifungal medications.
MATERIALS AND METHODS
Patients: Patients at least 13 years of age of any gender or race,
with proven, probable, or possible invasive fungal infection6 who were
able to swallow an oral suspension and comply with the treatment
regimen were eligible for study participation. Patients had to be
intolerant to, or have disease refractory to, standard antifungal therapy.
Patients were considered intolerant to standard therapies if they
experienced organ toxicity, had preexisting renal insufficiency, or
experienced idiosyncratic or major anaphylactic reactions to other
antifungal agents. For the purpose of this study, patients at high risk
for toxicity by virtue of their underlying disease or concomitant
medications also were considered intolerant to standard therapies.
Patients were considered to have refractory disease if their disease
progressed or if they failed to improve clinically, despite extended or
repetitive courses of antifungal therapy.
In accordance with the Declaration of Helsinki, written informed
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consent and approval by an accredited institutional review board were
obtained prior to initiation of any study-related activities.
Study design: In this open-label, multicenter clinical study, all
patients were treated with posaconazole (Schering Plough, Kenilworth,
NJ, USA) 800 mg daily given orally in divided doses (400 mg two
times daily or 200 mg four times daily). Patients were monitored at
weeks 1, 2, and 4, every month thereafter, at the end of treatment, and
for 30 days posttherapy. The protocol-defined treatment duration was
a maximum of 12 months; however, patients who required longer
therapy were eligible for enrollment in a separate treatment-use
extension protocol.
Clinical response: Clinical response to therapy was evaluated at
weeks 2 and 4, then monthly, and at the end of therapy. Treatment was
considered a success if a patient experienced a total resolution (complete
response) or improvement (partial response) in all attributable symptoms,
signs, and radiographic abnormalities, if present at enrollment. Treatment
was considered a nonsuccess if there was no improvement in attributable
symptoms, signs, and radiographic abnormalities, if present at enrollment
(stable disease), or if there was deterioration in attributable clinical or
radiographic abnormalities necessitating alternative antifungal therapy
or resulting in death (failure).
Safety assessments: Safety and tolerability were evaluated
throughout the study period. Adverse events were recorded and
categorized using the National Institute of Allergy and Infectious Diseases
(NIAID) AIDS grading system, when possible. When adverse events
did not fall into the NIAID categories, an alternative grading system
was used whereby adverse events were scored as mild, moderate, severe,
or life threatening. The relationship of each adverse effect to posaconazole
therapy (unlikely, possible, or probably) and whether the effect
necessitated premature discontinuation of therapy or hospitalization was
also assessed. Blood samples were collected at each visit during treatment
and at the final posttherapy visit for routine hematologic and chemistry
evaluations. In addition, a standard 12-lead electrocardiogram was
obtained at the baseline visit and at week 4.
RESULTS
 Eleven patients had proven chromoblastomycosis or eumycetoma
as determined by fungal cultures and one patient was diagnosed with
eumycetoma by histopathology. All patients had disease considered to
be refractory to standard therapies, but none were considered to be
intolerant. Most patients (11 of 12) were men with a mean age of 47
years. Six of the patients had eumycetoma; five were caused by
Madurella spp., and one was caused by S. apiospermum. Six patients
had chromoblastomycosis, all caused by F. pedrosoi. All patients had
a long disease history (range: 3 - 29 years). Sites of infection primarily
involved the skin and soft tissues of the lower extremities (foot and
leg); bone involvement was observed in five of six patients with
eumycetoma. Prior antifungal therapy consisted of ketoconazole and
itraconazole for patients with eumycetoma (total cumulative duration:
2 mo to ~ 27 mo) and terbinafine, itraconazole, and flucytosine for
patients with chromoblastomycosis (total cumulative duration: 17 mo
to ~ 8 y). Baseline patient characteristics are shown in Table 1.
Clinical success was achieved by five of six patients (four with
complete response, one with partial) with eumycetoma and by five of
six patients (four with complete response, one with partial) with
chromoblastomycosis. Overall, significant clinical improvement was
observed in nine patients during the first six months of posaconazole
therapy. At the end of treatment, negative fungal cultures were observed
in four patients with eumycetoma and in four patients with
chromoblastomycosis.
Of the two patients who were considered a nonsuccess (one with
eumycetoma; one with chromoblastomycosis) both had stable disease
at the end of posaconazole therapy. In patient 10, posaconazole therapy
halted the progression of chromoblastomycosis and resulted in some
Table 1
Patient demographics, etiologic and clinical characteristics
Patient Age Sex Disease Organism Site of infection (tissue involved) Duration of disease, y
(includes relapses
and remissions)
1* 35 M Eumycetoma M. grisea Foot, knee, leg (skin/subcutaneous tissue, bone) 13
2*† 40 M Eumycetoma M. grisea Foot, ankle (skin/subcutaneous tissue) 20
3 38 M Eumycetoma M. grisea Foot, ankle (skin/subcutaneous tissue, bone) 7
4*† 25 M Eumycetoma S. apiospermum Foot (skin/subcutaneous tissue, bone) 14
5 37 M Eumycetoma M. mycetomatis Foot (skin/subcutaneous tissue, bone) 23
6 50 M Eumycetoma M. mycetomatis Foot (skin/subcutaneous tissue, bone) 4
7 45 F Chromoblastomycosis F. pedrosoi Buttock (skin/subcutaneous tissue) 12
8 69 M Chromoblastomycosis F. pedrosoi Leg (skin/subcutaneous tissue) 4
9 55 M Chromoblastomycosis F. pedrosoi Leg (skin/subcutaneous tissue) 3
10* 47 M Chromoblastomycosis F. pedrosoi Legs, arm (skin/subcutaneous tissue) 16
11 69 M Chromoblastomycosis F. pedrosoi Leg (skin/subcutaneous tissue) 29
12 53 M Chromoblastomycosis F. pedrosoi Leg (skin/subcutaneous tissue) 8
*Patients received a second course of posaconazole therapy as part of a treatment-use extension protocol; †Second course of posaconazole therapy was given after a 10-
to 12-month treatment hiatus.
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symptomatic improvement. During the fourth month of posaconazole
therapy, the chromoblastomycosis worsened; a medical examination
revealed the patient had diabetes mellitus. Management of the diabetes
was associated with lesion improvement and decreased pain that resulted
in increased mobility and the ability to perform daily chores. Cultures
remained positive for F. pedrosoi at the end of treatment. After an
additional 11 months of posaconazole therapy (as part of a treatment-
use extension protocol), the patient’s disease relapsed and therapy was
discontinued. Diabetes was well controlled at the time of relapse. Clinical
summaries of all patients are provided in Table 2 and Table 3.
Patient 2 and patient 4, both of whom had a successful outcome,
had a relapse of eumycetoma after a 10- to 12-month treatment hiatus.
Both patients received a second course of posaconazole therapy as
part of a treatment-use extension protocol. Successful outcomes were
observed in both patients after the second course of posaconazole
therapy (Table 2). Currently, all lesions on patient 4 have disappeared,
and although osteomyelitis is still apparent on radiologic images of
the foot, he remains in good health.
Posaconazole was generally well tolerated by these 12 patients
with eumycetoma and chromoblastomycosis. Treatment-related adverse
events were headache (n = 2) and elevated bilirubin levels (n = 2). One
subject with hyperbilirubinemia had a baseline bilirubin value of 0.5
mg/dL and elevation was observed on day 50 of therapy with a
maximum value of 1.2 mg/dL. No elevations of transaminases were
seen in this subject and a final diagnosis of Gilbert’s disease was made.
The second subject with elevated bilirubin presented with elevated
transaminases at baseline and had intermittent elevation of bilirubin
during study. The patient’s maximum bilirubin value was 1.6 mg/dL.
Although patient 10 developed diabetes while on posaconazole therapy,
it was considered unrelated to therapy. No adverse events leading to
drug discontinuation occurred in the patients with eumycetoma or
chromoblastomycosis. Only one adverse event was considered serious
(headache) but unrelated to posaconazole. Posaconazole was not
associated with QTc prolongation or negative inotropic effects, and it
did not cause visual disturbances.
Representative case: eumycetoma (patient #2): A 40-year-old man
with a 20-year history of eumycetoma caused by M. grisea sought
treatment for nodules and fistulae on the left foot with osteolytic lesions
in the thalus, calcaneal, and navicular bones (patient 2; Fig. 1a). Before
study entry, several courses of itraconazole (cumulative duration, 10
mo) and ketoconazole (cumulative duration, 3 mo) therapy failed;
neither produced sustained microbiology and clinical improvement.
Salvage therapy with posaconazole was initiated.
Response to posaconazole therapy was first evident at month 3, at
which time the patient’s fistulae resolved, nodules became smaller, and
pain lessened. By month 6, his ankle nodules had resolved, but there
Table 2
Summary of patients treated with posaconazole for eumycetoma considered refractory to standard therapy
Prior Antifungal Therapy Posaconazole Therapy
Patient Drug Dose Cumulative Duration Response Response Outcome
(mg/d) duration (mo) (d) (6 mo) (end of treatment)
1 KTZ 400 6 1015 Knee and foot nodule Negative skin fungal cultures; Success (complete)
ITZ 200 6 improvement foot nodules resolved
2 ITZ 200 ~2 367 Resolution of ankle Skin absent of fungal Success (complete)
(Treatment ITZ 400 8 nodules; slight elements; resolution of
period 1) KTZ 400 3 recurrence of pain, tumor, nodules;
foot nodules negative fungal cultures
2 398 Resolution of pain; Negative skin fungal cultures; Success (complete)
(Treatment improved lesions, resolution of bone
period 2*) mobility abnormalities, pain,
tumor, nodules
3 ITZ 200 ~ 13 239 Ankle nodule was excised Overall improvement Success (complete)
4 ITZ 200 9 388 Improved signs Fungal cultures grew Success (partial)
(Treatment ITZ 300 1 and symptoms P. boydii and S. apiospermum;
period 1) ITZ 800 17 ongoing foot tumor and pain
4 445 Increased motility without Success (partial)
(Treatment pain; skin lesions resolved;
period 2*) evidence of osteomyelitis
5 KTZ 400 4 168 Improved signs and symptoms; negative skin Nonsuccess (stable)
fungal culture; continued evidence of eumycetoma
6 KTZ 800 2 252 No change in signs Negative skin fungal cultures/ Success (complete)
and symptoms histology of nodule biopsy;
normal radiology
*Treatment extension period; ITZ = itraconazole; KTZ = ketoconazole.
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was a slight recurrence of his foot nodules. Biopsy samples taken of the
lesion showed grains with dark hyphae, but fungal cultures were negative.
At the end of treatment (month 12), the nodules, edema, and pain had
resolved. Biopsy samples of the skin showed inflammation, but fungal
cultures were negative. Posaconazole therapy was discontinued.
The patient had a relapse after a 12-month treatment hiatus, at
which time he presented with edema, nodules, and fistulae on the left
foot and ankle with associated motion-related pain. Radiographic results
revealed an osteolytic lesion in the calcaneus bone and periostitis of
the first metatarsal. Posaconazole therapy was restarted as part of a
treatment-use extension protocol. Nodule size, pain, and edema
diminished by month 2. By month 6, his foot pain had resolved, he had
greater ankle motility, and the fistulae closed. At his 9-month visit, his
left foot and ankle lesions were greatly reduced; however, a nodule in
the left Achilles’ tendon was noted. Surgical excision of the ankle nodule
was performed after 11 months of posaconazole therapy. Histologic
and mycologic examination of the nodule showed inflammation but
no fungal elements. The patient tolerated posaconazole well and
remains on posaconazole therapy. Recent imaging of the foot shows
resolution of all bone lesions (Fig. 1b).
Representative case: chromoblastomycosis (patient #11). A 69-
year-old man with a 29-year history of chromoblastomycosis caused
by F. pedrosoi sought treatment for ulcerated nodules on his left leg
(patient 11; Fig. 2a). Before study entry, several courses of standard
antifungal therapy had failed, among them amphotericin B (duration
of therapy unknown), itraconazole (> 2-y duration), flucytosine (~ 1-y
duration), and terbinafine (1-y duration).
Response to posaconazole therapy was evident first at month 1, at
which time ulcerated nodules had improved. A culture of a skin specimen
collected at this time was positive for F. pedrosoi. The ulcerated nodules
did not change between the 1-month and 3-month visits; however, by
month 6, they had improved considerably. Skin cultures were negative
for F. pedrosoi at month 4; five additional skin cultures performed between
months 5 and 10 also were negative for this fungus. Continued clinical
improvement was noted at months 8 and 12 (Fig. 2b).
DISCUSSION
Because the causative fungal pathogens may prove resistant to
conventional antifungal therapies, eumycetomas and
chromoblastomycoses are challenging infections to manage. Many
patients experience remitting and relapsing disease and suffer from
disfigurement and discomfort for years. Although long-term medical
therapy usually is needed to produce a sustained clinical response,
tolerability and adverse events may reduce the likelihood of achieving
it. As a result, clinical success rates of both pharmacologic and
nonpharmacologic therapies published thus far in the literature remain
unacceptably low, demonstrating the need for new therapies.
However, the assessment of therapies for these infections is difficult
because of the chronic nature of the disease and the observed high
Table 3
Summary of patients treated with posaconazole for chromoblastomycosis considered refractory to standard therapy
Prior Antifungal Therapy Posaconazole Therapy
Patient Drug Dose Cumulative Duration Response Response Outcome
(mg/d) duration (mo) (d) (6 mo) (end of treatment)
7 TRB 500 12 376 Skin lesion Skin lesion resolved; Success (complete)
ITZ 400 24 improvement negative skin fungal culture
8 ITZ 200 10 268 Leg nodule Ongoing mild nodules Success (partial)
TRB 250 2 improvement
ITZ 300 5
9 ITZ 200 6 174 Ulcer resolved; negative fungal culture Success (complete)
TRB 1000 16
10 ITZ 100–300 ~ 62 375 Lesions and pain Lesion improvement; Nonsuccess (stable)
(Treatment FC 1000 8 persisted; skin cultures skin cultures positive
period 1) TRB 1000 12 positive for F. pedrosoi for F. pedrosoi
SAP 200 18
10 293 Symptomatic Symptomatic improvements Nonsuccess
(Treatment  improvement; for 11 mo; cultures (mycosis reactivated)
period 2*) skin cultures positive  remained positive; disease
for F. pedrosoi worsened, POS discontinued
11 ITZ 200 29 343 Nodule improvement; Negative sequential Success (complete)
FC 750 10 negative fungal culture fungal cultures
TRB 1000 12
12 ITZ 200 58 182 Resolution of skin ulcers; negative fungal cultures Success (complete)
TRB 500 17
*Treatment extension period; FC = flucytosine; ITZ = itraconazole; KTZ = ketoconazole; POS = posaconazole; SAP = saperconazole; TRB = terbinafine.
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Fig. 1a - Computed tomography of the foot at presentation (treatment period 1) before
posaconazole therapy. Arrows show lytic lesions in the thalus, calcaneal, and navicular bones
(patient 2).
Fig. 1b - Computed tomography of the foot after the second course of posaconazole. (14
months). Arrows show complete resolution of calcaneal and navicular bone lesions (patient 2).
Fig. 2 - Response of chromoblastomycosis to posaconazole therapy (patient 11): A) at
presentation before posaconazole treatment; B) after 12 months of posaconazole therapy.
relapse rate. For example, in the case of eumycetomas, clinical
assessment includes changes in nodule diameter and the amount of
purulent secretions, and the disappearance of sinus tracts. Eradication
of the pathogen is difficult to prove, even when deep biopsies are
performed. In our experience, we have observed relapses in several
patients in whom bone biopsy cultures were negative. Additionally,
clinical response varies by the causative species. Because of these
circumstances, long-term follow up is required for these patients.
In the current study, posaconazole therapy produced successful
clinical outcomes in five of six patients with eumycetoma and five of
six patients with chromoblastomycosis considered refractory to
conventional therapies. In many patients, posaconazole therapy resulted
in significant clinical improvements, often within the first six months
of therapy, and was well tolerated during long-term (up to 1015 d)
administration. Successful outcome was associated with various
symptomatic improvements; lesion diameter decreased, fistula closed,
secretions lessened, pain and swelling resolved, and motility increased.
Resolution of bone abnormalities also were observed in patients with
eumycetoma infections that caused osteomyelitis, suggesting that
posaconazole may penetrate this tissue after oral administration.
Although two patients had stable disease at the end of treatment
and thus were considered nonsuccesses, this outcome may be of
significant clinical importance to patients who had progressive or
worsening disease before posaconazole therapy. For example, patient
344
NEGRONI, R.; TOBÓN, A.; BUSTAMANTE, B.; SHIKANAI-YASUDA, M.A.; PATINO, H. & RESTREPO, A. - Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.
Rev. Inst. Med. trop. S. Paulo, 47(6):339-346, 2005.
10 had chromoblastomycosis that was progressing significantly prior
to initiating treatment. Posaconazole therapy halted the progression
and resulted in significant symptomatic improvements for most of the
first year of treatment. Although this patient was considered to have
stable disease at the end of therapy, the clinical improvement associated
with posaconazole therapy improved patient’s ability to walk and to
perform daily chores. Regaining the ability to perform these activities
may offer some therapeutic advantage in these challenging-to-manage
chronic diseases. After completing the study, patient 10 continued to
receive posaconazole therapy as part of a treatment-use extension
protocol. The first few months of additional posaconazole therapy were
associated with symptomatic improvement; however, after 11 months,
the patient suffered a relapse and posaconazole therapy was
discontinued owing to treatment failure. The failure was not thought
to be due to diabetes, as this condition had been well controlled.
Although the susceptibility of the eumycetoma causing fungal
pathogens to the azoles varies greatly, they often are tried because the
causative organisms generally are resistant to amphotericin B41; thus,
therapeutic options are limited. In susceptibility studies, reported
minimum inhibitory concentration (MIC) ranges of fluconazole and
itraconazole against P. boydii are 32 µg/mL to > 64 µg/mL and 0.5 µg/
mL to 4 µg/mL, respectively20,52. Itraconazole MICs range from 0.25 µg/
mL to 8 µg/mL against S. apiospermum (the teleomorph of P. boydii)26,33.
Additionally, clinical outcome following treatment with azoles is variable.
Reported response rates after azole treatment of eumycetoma range from
40% with itraconazole to 70% with ketoconazole41. Several small studies
have reported successful outcome following treatment with itraconazole
monotherapy11,19,41, combination therapy with itraconazole plus surgery46
or ketoconazole plus surgery27, and combined itraconazole/flucytosine
therapy8. Voriconazole, a newer azole antifungal, has demonstrated in
vitro activity against a wide range of moulds, including F. pedrosoi (MIC
≤ 0.03-1 µg/mL)26 and S. apiospermum (MIC 0.03-0.5 µg/mL)26,33,44,48.
Currently, there are no reports regarding the efficacy of voriconazole
against eumycetoma due to Madurella spp.; however, voriconazole
therapy has been used successfully to treat subcutaneous S. apiospermum
infection in two patients12,25.
The fungal pathogens that cause chromoblastomycosis also are
typically resistant to conventional pharmacologic therapies. DE
BEDOUT et al.15 reported that 67% of F. pedrosoi isolates are resistant
to fluconazole (MIC ≥ 20 µg/mL), 58% are resistant to flucytosine
(MIC ≥ 25 µg/mL), and 33% are resistant to amphotericin (MIC ≥ 4
µg/mL)15. F. pedrosoi also has demonstrated resistance to
itraconazole4,37. Considerable variability has been observed among
conventional antifungal therapies regarding clinical efficacy in the
treatment of chromoblastomycosis. In a retrospective review of 51 cases
in Mexico, BONIFAZ et al. reported that conventional therapies
(cryosurgery, itraconazole, topical heat, amphotericin B, 5-flucytosine,
ketoconazole, and calciferol) resulted in clinical cure in only 31% (16/
51) of patients with chromoblastomycoses9. Ketoconazole is associated
with only modest (32%) improvement in chromoblastomycosis of
slight-to-moderate severity and generally is considered ineffective in
extensive disease41. Itraconazole monotherapy has demonstrated clinical
effectiveness in patients with infection caused by C. carrionii or F.
pedrosoi8,11,29,40,42; however, its efficacy appears to be inversely
associated with disease severity40,42. Concomitant cryotherapy has been
associated with improved outcomes9,10,28, as has the addition of
flucytosine8 or terbinafine (combination or alternate-week therapy)22
in more extensive cases caused by F. pedrosoi. Saperconazole
demonstrates superior in vitro and in vivo activity against F. pedrosoi
in mice compared with itraconazole and ketoconazole13, but its clinical
effect remains to be evaluated.
Other therapies have been examined for potential effectiveness.
Although 5-flucytosine has been associated with clinical success in
small numbers of patients, this drug is not uniformly available in
endemic areas39, and resistance commonly develops during prolonged
courses of therapy41,54. Thiabendazole, a commonly used antihelmintic,
is effective in less than 50%41 of patients, but its use is limited by
gastrointestinal toxicities, especially at doses greater than 2 g daily5,41.
A few case reports describe the clinical efficacy of terbinafine used
alone17,47 or in combination with heat therapy50. ESTERRE et al.
reported mycologic cure of chromoblastomycosis in 85.2% (23/27) of
patients after 12 months of terbinafine therapy18. In this pilot study,
the efficacy of terbinafine extended to patients with imidazole-refractory
or chronic disease18.
Posaconazole is a new, potent, extended-spectrum, antifungal agent.
It has demonstrated in vitro activity against many of the fungal
pathogens that cause eumycetoma and chromoblastomy-
cosis14,16,20,33,38,49,52. Previously published case reports describe the
efficacy of posaconazole in treating life-threatening infections caused
by Acremonium strictum24, S. apiospermum34, and Rhizopus spp.51 that
persisted despite itraconazole or amphotericin B therapy. Importantly,
posaconazole appears to penetrate bone. Posaconazole was used to
successfully treat disseminated phaeohyphomycosis due to Exophiala
spinifera with bone involvement in a 41-year-old woman with no known
immunosuppression38 and multidrug resistant disseminated aspergillosis
with bone involvement in a 64-year-old recipient of a lung transplant31.
A subanalysis of patients from the present study who had aspergillosis
refractory to or intolerant of conventional antifungal therapy showed
that posaconazole resulted in significantly more successful outcomes
(42% vs 26%; p < 0.006) and demonstrated a survival benefit compared
with an external control group55. Collectively, these observations support
posaconazole’s extended spectrum of antifungal activity and suggest
that this triazole will have broad clinical usefulness in the treatment of
invasive fungal infections.
Posaconazole appears to be safe and well-tolerated when
administered long term. Headache and gastrointestinal disorders
(nausea, diarrhea, vomiting, abdominal pain) are the most commonly
reported treatment-emergent, treatment-related adverse events21,45. To
date, posaconazole has not been associated with QTc prolongation nor
negative inotropic effects and posaconazole does not cause visual
disturbances. No major adverse events were described in case reports
of chronic posaconazole administration3,30,34,38,51, even when
administered continuously for longer than 20 months3. Posaconazole
inhibits activity of the hepatic enzyme cytochrome P450 (CYP) 3A4
but has no effect on CYP1A2, CYP2C8/9, CYP2D6, or CYP2E1
activity56, and it is not a substrate of the CYP450 enzyme system.
CONCLUSION
Posaconazole therapy led to successful outcome in 10 of 12 patients
with eumycetoma or chromoblastomycosis who had disease refractory
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to standard therapies. Clinical improvement observed in these patients
is noteworthy considering all had a long history of chronic disease, with
most having failed multiple prior therapies. Long-term posaconazole
therapy (> 2 y) was well tolerated; none of the patients discussed above
withdrew from the study because of adverse events. Furthermore, these
findings support the use of posaconazole as a treatment option for patients
with eumycetoma or chromoblastomycosis.
RESUMO
Tratamento com posaconazol de casos de cromoblastomicose e
micetoma maduromicótico resistentes a outros antifúngicos
Eumicetoma e cromoblastomicose são infecções fúngicas crônicas
do tecido subcutâneo que evoluem com aspecto desfigurado, raramente
involuindo espontaneamente. A maioria dos pacientes não apresenta
melhora sustentada por longo tempo com os tratamentos disponíveis,
sendo de grande importância as novas opções terapêuticas. A eficácia
do posaconazol, um novo agente antifúngico de amplo espectro do
grupo dos triazóis, foi estudada em 12 pacientes com eumicetoma ou
cromoblastomicose refratária às terapêuticas antifúngicas disponíveis.
Os pacientes receberam por no máximo 34 meses, doses divididas
de 800 mg/dia de posaconazol. Resposta clínica parcial ou completa
foi considerada como sucesso; doença estável ou falha terapêutica foi
considerada como insucesso.
Todos os 12 pacientes tinham infecções comprovadas ou prováveis,
refratárias à terapêutica padrão preconizada. Sucesso clínico foi registrado
em cinco de seis pacientes com eumicetoma e cinco de seis pacientes
com cromoblastomicose. Em dois pacientes observou-se doença estável.
Como parte do protocolo de extensão do tratamento, dois pacientes com
eumicetoma que inicialmente tinham tido sucesso terapêutico e que após
um intervalo maior de 10 meses apresentaram recidiva da micose, foram
retratados com sucesso com posaconazol. Posaconazol foi bem tolerado
durante o longo período de administração (até 1015 dias).
A terapêutica com posaconazol foi seguida de sucesso na maioria
dos pacientes com eumicetoma ou cromoblastomicose refratária à
terapêutica padrão, sugerindo que tal droga possa ser uma importante
opção no tratamento de tais doenças.
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